Brokerages Anticipate Bausch Health Companies Inc (NYSE:BHC) Will Announce Earnings of $1.08 Per Share

Wall Street analysts expect Bausch Health Companies Inc (NYSE:BHC) to post earnings of $1.08 per share for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Bausch Health Companies’ earnings, with the highest EPS estimate coming in at $1.34 and the lowest estimate coming in at $0.99. Bausch Health Companies reported earnings of $1.15 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 6.1%. The business is expected to issue its next quarterly earnings results on Tuesday, November 5th.

On average, analysts expect that Bausch Health Companies will report full-year earnings of $4.15 per share for the current year, with EPS estimates ranging from $4.08 to $4.37. For the next fiscal year, analysts anticipate that the business will report earnings of $4.40 per share, with EPS estimates ranging from $3.56 to $4.85. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Bausch Health Companies.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.03 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.03). Bausch Health Companies had a positive return on equity of 52.12% and a negative net margin of 10.88%. The business had revenue of $2.15 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same quarter last year, the firm posted $0.93 EPS. The company’s revenue was up 1.1% compared to the same quarter last year.

A number of research analysts have issued reports on BHC shares. TD Securities upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 price target for the company in a research report on Thursday, August 15th. Guggenheim started coverage on Bausch Health Companies in a research report on Thursday, September 12th. They set a “buy” rating and a $30.00 price target for the company. Wells Fargo & Co reiterated a “sell” rating on shares of Bausch Health Companies in a research report on Tuesday, September 17th. Wolfe Research started coverage on Bausch Health Companies in a research report on Friday, July 19th. They set an “outperform” rating and a $31.00 price target for the company. Finally, Mizuho set a $45.00 price target on Bausch Health Companies and gave the stock a “buy” rating in a research report on Thursday, June 20th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $29.68.

BHC stock traded up $0.13 during trading on Wednesday, reaching $21.83. 105,625 shares of the company’s stock were exchanged, compared to its average volume of 2,841,896. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 8.94. Bausch Health Companies has a 1-year low of $17.20 and a 1-year high of $28.45. The company’s fifty day moving average price is $22.06 and its 200-day moving average price is $23.42. The firm has a market cap of $7.64 billion, a PE ratio of 5.43 and a beta of 0.80.

In other news, CEO Joseph C. Papa acquired 30,000 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were bought at an average price of $23.31 per share, with a total value of $699,300.00. Also, insider William D. Humphries acquired 30,703 shares of the company’s stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $21.18 per share, for a total transaction of $650,289.54. The disclosure for this purchase can be found here. Insiders sold a total of 18,159 shares of company stock worth $410,355 in the last three months. Company insiders own 11.87% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. FIL Ltd raised its position in shares of Bausch Health Companies by 69.6% during the first quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock worth $260,170,000 after purchasing an additional 4,327,851 shares during the period. Vanguard Group Inc. raised its position in shares of Bausch Health Companies by 4.0% during the second quarter. Vanguard Group Inc. now owns 9,513,863 shares of the company’s stock worth $239,940,000 after purchasing an additional 363,579 shares during the period. Bank of Montreal Can raised its position in Bausch Health Companies by 43.7% during the second quarter. Bank of Montreal Can now owns 5,318,505 shares of the company’s stock valued at $134,133,000 after buying an additional 1,616,428 shares during the period. Renaissance Technologies LLC raised its position in Bausch Health Companies by 9.8% during the second quarter. Renaissance Technologies LLC now owns 3,037,200 shares of the company’s stock valued at $76,598,000 after buying an additional 272,000 shares during the period. Finally, Clearbridge Investments LLC raised its position in Bausch Health Companies by 0.5% during the first quarter. Clearbridge Investments LLC now owns 2,897,282 shares of the company’s stock valued at $71,563,000 after buying an additional 14,610 shares during the period. 56.01% of the stock is currently owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Recommended Story: Coverage Ratio

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.